The potential of retinoids for combination therapy of lung cancer: Updates and future directions

Tripathi, Surya Kant; Pandey, Kamal; Panda, Munmun; Spinella, Michael J.; Rengasamy, Kannan R.R.; Biswal, Bijesh K.

doi:10.1016/j.phrs.2019.104331

Cited by 19 publications

(9 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of resistance to standard chemotherapy indicates that single drugs may not be enough for cancer treatment. Combination therapy has received attention in recent years as a novel cancer treatment approach [ 147 ]. Traditional chemotherapeutics combined with therapy with phytochemicals like WS may enhance the therapeutic effectiveness in cancer treatment.…”

Section: Role Of Withania Somnifera In Cancermentioning

confidence: 99%

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics

et al. 2022

View full text Add to dashboard Cite

Chemotherapy is one of the prime treatment options for cancer. However, the key issues with traditional chemotherapy are recurrence of cancer, development of resistance to chemotherapeutic agents, affordability, late-stage detection, serious health consequences, and inaccessibility. Hence, there is an urgent need to find innovative and cost-effective therapies that can target multiple gene products with minimal adverse reactions. Natural phytochemicals originating from plants constitute a significant proportion of the possible therapeutic agents. In this article, we reviewed the advances and the potential of Withania somnifera (WS) as an anticancer and immunomodulatory molecule. Several preclinical studies have shown the potential of WS to prevent or slow the progression of cancer originating from various organs such as the liver, cervix, breast, brain, colon, skin, lung, and prostate. WS extracts act via various pathways and provide optimum effectiveness against drug resistance in cancer. However, stability, bioavailability, and target specificity are major obstacles in combination therapy and have limited their application. The novel nanotechnology approaches enable solubility, stability, absorption, protection from premature degradation in the body, and increased circulation time and invariably results in a high differential uptake efficiency in the phytochemical’s target cells. The present review primarily emphasizes the insights of WS source, chemistry, and the molecular pathways involved in tumor regression, as well as developments achieved in the delivery of WS for cancer therapy using nanotechnology. This review substantiates WS as a potential immunomodulatory, anticancer, and chemopreventive agent and highlights its potential use in cancer treatment.

show abstract

Section: Role Of Withania Somnifera In Cancermentioning

confidence: 99%

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the highly toxic effects of ATRA represent the main limitation for its use as a therapeutic agent in the treatment of lung cancer. In this regard, phycocyanin was found to function synergistically with ATRA and to reduce the toxicity as well as the side effects of lung cancer. ,, …”

Section: Discussionmentioning

confidence: 99%

Bioactive Compounds of Arthrospira spp. (Spirulina) with Potential Anticancer Activities: A Systematic Review

Silva

et al. 2021

ACS Chem. Biol.

View full text Add to dashboard Cite

Arthrospira, a genus of blue-green cyanobacteria, is known for its great biological activity due to the presence of a large number of substances that are potentially active against tumor cells. This review aimed to evaluate the potential of Arthrospira spp. for the treatment or reduction of several types of cancer, in addition to elucidating the mechanism of action by which their compounds act on tumor cells. A systematic review was carried out in PubMed, Science Direct, LILACS, and SciELO databases, including original studies from 2009 to 2020. A total of 1306 articles were independently assessed according to the eligibility criteria, of which 20 articles were selected and assessed for the risk of bias using seven criteria developed by the authors. Arthrospira spp. of cyanobacteria have been evaluated against eight different types of cancer, mainly colon cancer. Among all the compounds, phycocyanin was the most used, followed by peptides and photosensitizers. In general, compounds from Arthrospira spp. act as anticancer agents by inhibiting the proliferation of tumor cells, triggering cell cycle arrest, and inducing apoptosis via different signaling pathways. In addition, these compounds also exhibited antioxidant, antiangiogenic, and antimetastatic activities. Phycocyanin demonstrated better efficacy against several types of cancer via different activities and therapeutic targets. Furthermore, it was the only molecule that functioned in synergy with other drugs that are already well established for the treatment of cancer.

show abstract

“…The loss of RARβ might contribute to enhanced cancer stemness and the apoptosis resistance of CSCs to gefitinib in NSCLC cells. ATRA can induce the apoptosis of NSCLC CSCs through activation of RARβ and its ability to downregulate the CSCs markers in lung cancer cells [42,43]. The expression of RARβ as well as RXRβ was reported to be downregulated in NSCLC, which enabled the cancer cell to evade apoptosis [44].…”

Section: Discussionmentioning

confidence: 99%

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

et al. 2020

View full text Add to dashboard Cite

Background: The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1 bright /CD44 high expression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells. Methods: Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay, Results: GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB. Conclusion: Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1 bright /CD44 high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.

show abstract

The potential of retinoids for combination therapy of lung cancer: Updates and future directions

Cited by 19 publications

References 117 publications

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics

Bioactive Compounds of Arthrospira spp. (Spirulina) with Potential Anticancer Activities: A Systematic Review

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

Contact Info

Product

Resources

About